{"nctId":"NCT00007020","briefTitle":"Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid","startDateStruct":{"date":"1992-01"},"conditions":["Infantile Refsum's Disease","Zellweger Syndrome","Adrenoleukodystrophy","Peroxisomal Disorders","Cholestasis"],"count":85,"armGroups":[{"label":"Cholic Acid","type":"OTHER","interventionNames":["Drug: Cholic Acids"]}],"interventions":[{"name":"Cholic Acids","otherNames":["Cholic","Cholic Acid","Cholic Acid Capsules"]}],"eligibilityModule":{"eligibilityCriteria":"PROTOCOL ENTRY CRITERIA:\n\n--Disease Characteristics--\n\nClinical or biochemical evidence of liver disease, unexplained fat-soluble vitamin malabsorption, or peroxisomal dysfunction that compromises bile acid biosynthesis\n\nInclusion criteria for enrollment were:\n\n* Infants \\< age 3 months\n* Children presenting for evaluation of cholestasis defined as a conjugated bilirubin \\> 2mg/dl or increased serum bile acids\n* Older subjects of any age with cholestatic liver disease if urine screens suggested that they had inborn errors of bile acid metabolism\n* Confirmation of a diagnosis of an inborn error of bile acid synthesis based upon urine analysis by FAB-MS to determine whether specific abnormalities in bile acid synthesis are indicated\n* The patient and/or parent/legal guardian must have signed the written informed consent document before study start.\n* The patient must be willing and able to comply with all study assessments and procedures.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Excretion of Atypical Bile Acids in Urine by Category","description":"Patients with excretion of atypical bile acids in urine by category, from worst status before treatment (baseline, BL) to best status on treatment (OT)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Liver Function Tests (LFTs) Measured in Serum","description":"Patients with elevations of liver function tests (alanine transaminase \\[ALT\\], aspartate transaminase \\[AST\\]) measured as multiples of the upper limit of normal (ULN) at baseline (worst value) and on treatment (best value)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Liver Histology","description":"Patients (number, percentage) with pathological findings for qualitative (the presence of inflammation, fibrosis, necrosis, giant cells and cholestasis) and quantitative (the degrees of the aforementioned histologic features) liver histopathology at baseline (BL) and on treatment (OT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Height and Weight","description":"Change in height/weight percentiles from baseline (worst value) to the best on-treatment value, based on CDC (Centres for Disease Control and Prevention, US) growth chart percentiles","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":"5.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":"6.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":"3.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.3","spread":"4.8"}]}]}]},{"type":"SECONDARY","title":"Adverse Events","description":"Number of patients with any adverse event","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Bilirubin Measured in Serum","description":"Bilirubin concentration in serum at baseline and on treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"5.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"10.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"5.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":79},"commonTop":["Pyrexia","Upper respiratory tract infection","Fracture","Convulsion","Diarrhoea"]}}}